Ignite Creation Date:
2025-12-25 @ 4:53 AM
Ignite Modification Date:
2026-03-09 @ 11:29 AM
Study NCT ID:
NCT01555918
Status:
COMPLETED
Last Update Posted:
2013-02-01
First Post:
2012-03-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers
Sponsor:
Astellas Pharma Inc
Organization:
Study Overview
Official Title:
A Phase I, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the pharmacokinetic properties of isavuconazole (BAL4815) and the cleavage product (BAL8728) and assess the safety and tolerability after single-dose and steady state (multiple-dose) administration of isavuconazole BAL8557 in healthy Chinese subjects.
Detailed Description:
This is a two part study:
Part 1: On Day 1, Period 1, subjects will receive a single dose of isavuconazole orally or intravenously according to the treatment sequence allocation. Subjects will remain resident in the unit in order to collect blood for pharmacokinetics (PK) and to assess the safety tests. They will be released in the morning of Day 15 after collection of blood for safety tests. Subjects will have a washout period of 2 weeks returning to the unit for Day -1 of Period 2 (Day 29). Subjects will receive a single dose of isavuconazole orally or intravenously (opposite mode of administration from Period 1). Subjects will remain resident in the unit and will be released in the morning of Day 15, Period 2 (Day 44) after collection of blood for tests.
Part 2: Subjects will be allocated to multiple intravenous (IV) (Group 1) or oral (Group 2) dosing. On Day 1, Group 1 will receive multiple intravenous (IV) dosing of isavuconazole as a 2-hour infusion, three times a day (TID) with 8 hours between doses for 2 days followed by isavuconazole as a 2-hour infusion every day (QD) for 10 days. Group 2 will receive multiple oral (PO) dosing of isavuconazole TID with 8 hours between doses for 2 days followed by isavuconazole PO QD for 10 days. Subjects in Group 1 and 2 will remain resident in the unit in order to collect blood and urine for PK evaluations and to assess the safety tests. They will be released in the morning of Day 26 after collection of blood for tests.
Part 1: On Day 1, Period 1, subjects will receive a single dose of isavuconazole orally or intravenously according to the treatment sequence allocation. Subjects will remain resident in the unit in order to collect blood for pharmacokinetics (PK) and to assess the safety tests. They will be released in the morning of Day 15 after collection of blood for safety tests. Subjects will have a washout period of 2 weeks returning to the unit for Day -1 of Period 2 (Day 29). Subjects will receive a single dose of isavuconazole orally or intravenously (opposite mode of administration from Period 1). Subjects will remain resident in the unit and will be released in the morning of Day 15, Period 2 (Day 44) after collection of blood for tests.
Part 2: Subjects will be allocated to multiple intravenous (IV) (Group 1) or oral (Group 2) dosing. On Day 1, Group 1 will receive multiple intravenous (IV) dosing of isavuconazole as a 2-hour infusion, three times a day (TID) with 8 hours between doses for 2 days followed by isavuconazole as a 2-hour infusion every day (QD) for 10 days. Group 2 will receive multiple oral (PO) dosing of isavuconazole TID with 8 hours between doses for 2 days followed by isavuconazole PO QD for 10 days. Subjects in Group 1 and 2 will remain resident in the unit in order to collect blood and urine for PK evaluations and to assess the safety tests. They will be released in the morning of Day 26 after collection of blood for tests.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: